Willis Towers Watson Public Limited Company

WTW · NASDAQ

Market closed$293.45$-0.883000 (-0.30%)After hours $293.43 · -0.01%

Key statistics

Previous close$294.33
Open$298.20
Day high$301.98
Day low$292.71
52-week high$352.79
52-week low$240.61
Market cap27.72B
Volume643.80K
Average volume755.25K
P/E ratio16.51
Forward P/E
EPS17.77
Dividend yield+1.28%

Market context

Why it moved

WTW shares rose sharply, likely buoyed by positive sector momentum in the insurance brokerage and professional services space, as peer companies like Marsh & McLennan (MRSH) also traded higher amid broadly constructive analyst sentiment and anticipation of upcoming Q2 earnings results across the industry.

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Willis Towers Watson closed modestly lower, pulling back after a strong recent run, as investors weigh a busy news cycle of product launches and analyst activity ahead of its Q2 earnings report scheduled for July 30. The company launched KwantSure, an embedded digital insurance program for subcontractors, and unveiled an updated Geospatial Mortality Model for the U.S. pension risk transfer market, signaling continued innovation in analytics and distribution. Analyst sentiment remains broadly constructive — Mizuho holds a Buy with a $361 target, UBS rates it Buy at $382, and Piper Sandler raised its target to $317 — while Bank of America maintained a Hold, reflecting some valuation caution. The consensus average target of ~$338 implies roughly 15% upside from current levels.

-0.3

July 16, 2026Willis Towers Watson rose over 3% amid a wave of positive analyst activity and strong sector momentum, with insurance brokers outperforming as financial ETFs hit new 52-week highs. Piper Sandler raised its price target to $317 (from $283) while maintaining an Overweight rating, adding to recent upgrades from UBS ($382), Mizuho ($361), Wells Fargo ($341), and Keefe, Bruyette & Woods ($381) — with the consensus average target at ~$338, implying significant further upside. The advance also coincided with WTW's $0.96 quarterly dividend payment and a new embedded insurance partnership with Kwant, while investors look ahead to Q2 2026 earnings on July 30.

3.2302

July 15, 2026Willis Towers Watson closed modestly lower as analyst activity and an upcoming earnings catalyst shaped investor sentiment. Piper Sandler raised its price target to $317 from $283 while maintaining an Overweight rating, and Mizuho Securities reiterated its Buy rating with a $361 target — both well above the current price and suggesting meaningful upside. With Q2 2026 results scheduled for July 30, investors are positioning ahead of the earnings release. The broader insurance broker sector remains supported by rising risk complexity and Strait of Hormuz tensions, which are driving demand for marine and war-risk coverage.

-1.2537

July 14, 2026Willis Towers Watson closed down 2.3% and extended losses into after-hours trading, underperforming insurance broker peers as investors await the company's Q2 2026 earnings report scheduled for July 30. The decline comes amid a broadly mixed financial services session, despite strong Wall Street bank earnings driven by record investment banking activity. Notably, peer Marsh & McLennan recently raised its quarterly dividend by 10%, while consensus analyst price targets for WTW imply roughly 14% upside from recent levels, suggesting the pullback may reflect pre-earnings caution rather than fundamental deterioration.

-2.3042

July 14, 2026Willis Towers Watson rose over 2%, outperforming the broader financial services sector, as the company announced it will report Q2 2026 earnings on July 30 before market open — a catalyst putting the stock in focus ahead of a busy earnings season for financials. Investor sentiment was further supported by billionaire David Abrams holding WTW as a top position (4.5% of his portfolio) and a valuation analysis suggesting the stock may be 35% undervalued on an intrinsic value basis, even as near-term geopolitical tensions from resumed U.S.-Iran hostilities created broader macro uncertainty. Volume came in well below average, suggesting the move was driven more by sentiment and pre-earnings positioning than heavy institutional flows.

2.0369

July 11, 2026Willis Towers Watson closed essentially flat on the regular session but slipped in after-hours trading as investors weigh a mixed picture ahead of Q2 earnings. UBS reiterated its Buy rating with a $382 price target, while Cantor Fitzgerald raised its price target to $344 (from $322) citing share buybacks, though maintained a Neutral stance. An earnings preview shows analysts expect Q2 EPS of $3.13 (+9.4% YoY) with WTW having beaten estimates in each of its last four quarters. Broader peer pressure also looms, with WTW lagging industry peers over the past three months and trading at a discount to the group.

0.1798

July 10, 2026Willis Towers Watson shares closed modestly lower, pressured by broader market weakness tied to escalating U.S.-Iran geopolitical tensions that drove oil prices sharply higher and revived inflation concerns. The pullback comes despite a wave of constructive analyst activity: UBS raised its price target to $382 (from $374) maintaining Buy, Wells Fargo lifted its target to $341, Mizuho raised to $361, and KBW nudged its target to $381 — all ahead of an upcoming Q2 earnings report where analysts expect EPS of $3.13, up ~9% year-over-year. WTW continues to trade at a notable discount to peers and its average analyst target of ~$333, even as the company recently enhanced its RiskAgility actuarial platform with GPU execution capabilities.

-1.1792

July 9, 2026Willis Towers Watson closed modestly lower amid a broader market risk-off session triggered by President Trump declaring the Iran ceasefire deal 'over,' sending oil prices surging over 5% and pressuring financial stocks broadly. Despite the macro headwinds, analyst sentiment remained constructive: UBS raised its price target to $382 (from $374) maintaining a Buy rating, Keefe Bruyette & Woods nudged its target to $381, and BMO reiterated Outperform ahead of Q2 earnings, where analysts project EPS of $3.13, up ~9% year-over-year. However, WTW has meaningfully lagged insurance broker peers, gaining just 1.1% over three months versus the industry's 9.4%, a valuation gap that Zacks flagged today as a potential discount opportunity.

-0.4491

Zacks Investment Research · July 17, 2026WTW Lags Industry, Trades at a Discount: What Investors Should Do Now?marketscreener.com · July 15, 2026Willis Towers Watson US LLC And Kayna Partner With Kwant To Launch Embedded Insurance Program For Subcontractorswww.marketscreener.com · July 13, 2026Willis Towers Watson Public : WTW to Announce Second Quarter Earnings on July 30, 2026Barchart.com · July 8, 2026Willis Towers Watson's Quarterly Earnings Preview: What You Need to KnowMoomoo · July 8, 2026Keefe, Bruyette & Woods Adjusts Price Target on Willis Towers Watson Public to $381 From $380TradingView · June 26, 2026WTW Stock Declines 21.4% YTD: What Should Investors Do Now?Seeking Alpha · April 30, 2026Willis Towers Watson stock slumps after disappointing Q1 revenue (WTW:NASDAQ)Investing.com · April 30, 2026Willis Towers Watson stock hits 52-week low at $259.59
Benzinga · July 15, 2026WTW's Willis Business Collaborates With Kwant To Roll Out KwantSure Digital Insurance Program
Mt Newswire · July 15, 2026Piper Sandler Adjusts Price Target on Willis Towers Watson Public to $317 From $283, Maintains Overweight Rating
Benzinga · July 15, 2026Piper Sandler Maintains Overweight on Willis Towers Watson, Raises Price Target to $317
Mt Newswire · July 9, 2026Mizuho Securities Adjusts Willis Towers Watson Price Target to $361 From $338
Benzinga · July 9, 2026Mizuho Maintains Outperform on Willis Towers Watson, Raises Price Target to $361
Mt Newswire · July 9, 2026Wells Fargo Adjusts Price Target on Willis Towers Watson to $341 From $319
Benzinga · July 8, 2026UBS Maintains Buy on Willis Towers Watson, Raises Price Target to $382
Mt Newswire · July 8, 2026UBS Adjusts Price Target on Willis Towers Watson Public to $382 From $374, Maintains Buy Rating

Peers